18752700|t|A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies.
18752700|a|BACKGROUND: The aim of this study is to investigate the diagnostic value of perfusion 99mTc-exametazime single photon emission computed tomography (SPECT) in the diagnosis of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) in comparison with dopaminergic 123I-2beta-carbomethoxy-3beta-(4-iodophenyl)-n-(3-fluoropropyl) nortropane (FP-CIT) SPECT imaging. METHODS: Subjects underwent 99mTc-exametazime scanning (39 controls, 36 AD, 30 DLB) and 123I-FP-CIT scanning (33 controls, 33 AD, 28 DLB). For each scan, five raters performed visual assessments blind to clinical diagnosis on selected transverse 99mTc-exametazime images in standard stereotactic space. Diagnostic accuracy of 99mTc-exametazime was compared to 123I-FP-CIT results for the clinically relevant subgroups AD and DLB using receiver operating characteristic (ROC) curve analysis. RESULTS: Inter-rater agreement for categorizing uptake was "moderate" (mean kappa = 0.53) for 99mTc-exametazime and "excellent" (mean kappa = 0.88) for 123I-FP-CIT. For AD and DLB, consensus rating matched clinical diagnosis in 56% of cases using 99mTc-exametazime and 84% using 123I-FP-CIT. In distinguishing AD from DLB, ROC analysis revealed superior diagnostic accuracy with 123I-FP-CIT (ROC curve area 0.83, sensitivity 78.6%, specificity 87.9%) compared to occipital 99mTc-exametazime (ROC curve area 0.64, sensitivity 64.3%, specificity 63.6%) p = 0.03. CONCLUSION: Diagnostic accuracy was superior with 123I-FP-CIT compared to 99mTc-exametazime in the differentiation of DLB from AD.
18752700	16	33	99mTc-exametazime	Chemical	-
18752700	38	49	123I-FP-CIT	Chemical	MESH:C087552
18752700	97	116	Alzheimer's disease	Disease	MESH:D000544
18752700	121	146	dementia with Lewy bodies	Disease	MESH:D020961
18752700	234	251	99mTc-exametazime	Chemical	-
18752700	323	348	dementia with Lewy bodies	Disease	MESH:D020961
18752700	350	353	DLB	Disease	MESH:D020961
18752700	359	378	Alzheimer's disease	Disease	MESH:D000544
18752700	380	382	AD	Disease	MESH:D000544
18752700	492	498	FP-CIT	Chemical	MESH:C087552
18752700	543	560	99mTc-exametazime	Chemical	-
18752700	587	589	AD	Disease	MESH:D000544
18752700	594	597	DLB	Disease	MESH:D020961
18752700	603	614	123I-FP-CIT	Chemical	MESH:C087552
18752700	641	643	AD	Disease	MESH:D000544
18752700	648	651	DLB	Disease	MESH:D020961
18752700	761	778	99mTc-exametazime	Chemical	-
18752700	841	858	99mTc-exametazime	Chemical	-
18752700	875	886	123I-FP-CIT	Chemical	MESH:C087552
18752700	933	935	AD	Disease	MESH:D000544
18752700	940	943	DLB	Disease	MESH:D020961
18752700	1100	1117	99mTc-exametazime	Chemical	-
18752700	1158	1169	123I-FP-CIT	Chemical	MESH:C087552
18752700	1175	1177	AD	Disease	MESH:D000544
18752700	1182	1185	DLB	Disease	MESH:D020961
18752700	1253	1270	99mTc-exametazime	Chemical	-
18752700	1285	1296	123I-FP-CIT	Chemical	MESH:C087552
18752700	1316	1318	AD	Disease	MESH:D000544
18752700	1324	1327	DLB	Disease	MESH:D020961
18752700	1385	1396	123I-FP-CIT	Chemical	MESH:C087552
18752700	1479	1496	99mTc-exametazime	Chemical	-
18752700	1617	1628	123I-FP-CIT	Chemical	MESH:C087552
18752700	1641	1658	99mTc-exametazime	Chemical	-
18752700	1685	1688	DLB	Disease	MESH:D020961
18752700	1694	1696	AD	Disease	MESH:D000544
18752700	Negative_Correlation	MESH:C087552	MESH:D000544
18752700	Negative_Correlation	MESH:C087552	MESH:D020961

